Chemical conjugate of recombinant deleted human keratinocyte growth factor type I

A technology of keratinocytes and growth factors, applied in the field of genetic engineering, to achieve the effect of protecting acute small intestinal mucosal injury and acute liver injury

CN102260342AInactive Publication Date: 2011-11-30CHONGQING FAGEN BIOMEDICAL
3 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2011-11-30
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a conjugate obtained by chemically modifying recombinant deleted human keratinocyte growth factor type I by using polyethylene glycol molecules. It is characterized in that the activated polyethylene glycol molecule with a molecular weight of 5K-40K is covalently covalent with the free sulfhydryl group of the 17th cysteine ​​of the recombinant human keratinocyte growth factor type I (Δ23KGF-I) missing 23 amino acids at the N-terminal chemically coupled, and then purified by column chromatography to separate and purify the polyethylene glycol keratinocyte growth factor. The conjugate, while retaining the biological effect of human keratinocyte growth factor, changes its metabolic dynamics in vivo, and has preventive and therapeutic effects on digestive tract mucosal injury or ulcerative mucositis and acute chemical liver injury caused by radiotherapy and chemotherapy. therapeutic value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The invention relates to the field of genetic engineering, in particular to the recombinant preparation of deleted human keratinocyte growth factor type I, the polyethylene glycol modification of the deleted human keratinocyte growth factor type I, as well as the purification after modification and its application. Background technique

[0002] So far, two keratinocyte growth factors (KGF) have been discovered, namely keratinocyte growth factor type I (KGF-I) and keratinocyte growth factor type II (KGF-II). They are members of the fibroblast growth factor (FGF) family, and are also named FGF-7 and FGF-10 (Aaronoson SA.et al.J.Annals of the New York Academy of science, 1991, 638 : 62-77.). KGF-I was originally isolated and purified from the culture supernatant of human fetal lung fibroblasts by Rubin et al. (Rubin, JS, et al. Proc Natl Acad Sci USA, 1989.86(3): p.802-6.) , And found to promote mitosis of mouse keratinocytes, so it was named keratinocyte gr...

Examples

example 1

[0031] Example 1. Recombinant expression of human keratinocyte growth factor type I (Δ23hKGF) lacking 23 amino acids at the N-terminal

[0032] According to the Δ23hKGF amino acid sequence (SEQ ID No: 1), the corresponding cDNA sequence of the E. coli preferred codon was designed to include the 5'end and 3'respectively to design the restriction enzyme Nde I and BamH I sites (SEQ ID No: 2) . Entrusted Bao Bioengineering (Dalian) Co., Ltd. to artificially synthesize the entire gene and insert it into the pUC18 vector and named it pUC18-Δ23hKGF / DH5α.

[0033] Plasmid pUC18-Δ23hKGF DH5α and expression vector plasmid pET-3c were digested with restriction enzymes Nde I and BamH I. According to the results of 1% agarose electrophoresis, a fragment of about 4638 bp after digestion with pET-3c was recovered, and pUC18- After Δ23hKGF / DH5α is a fragment of about 450 bp after digestion, connect the two fragments with T4 ligase, use LA (tryptone 2g, yeast extract 1g, NaCl 2g, agar 3g, add wate...

example 2

[0035] Example 2. Purification and preparation of Δ23hKGF

[0036] Take out the bacteria from the refrigerator at -20℃, and put in the bacterial lysate (50mmol / L Tris-HCl, 5mmol / LEDTA, 10μg / ml DNase, 2mm MgCl at 1:15w / v) 2 , PH 8.5-9.0), add trisodium citrate with a final concentration of 0.1M when stirring at 37°C until the cleavage solution is not viscous, and continue stirring for 0.5h. Adjust the pH to 7.5, centrifuge at 10,000 rpm for 15 minutes, and collect the supernatant. The supernatant was applied to an SP-Sepharose Fast Flow column (equilibration solution: 50mmpb, pH7.5), re-equilibrated, and eluted with a linear gradient of 50-500mm Nacl. The elution peaks were collected and detected by SDS-PAGE to determine the main target protein. Elution peak. The target sample eluted by SP was applied to a Heparin column (equilibration solution: 20mm pb, pH 7.5), re-equilibrated, and eluted with a linear gradient of 50-500mm Nacl. The elution peaks were collected and detected by ...

example 3

[0037] Example 3: mPEG-MAL-20K modification of Δ23hKGF and purification of modified (PEG-20K-Δ23KGF)

[0038] For Δ23hKGF solution with a purity greater than 95%, use 100mmol / L phosphate buffer, pH6.5, dilute the sample to 2mg / mL, and press Δ23hKGF and mPEG-MAL-20KD (linear type, purchased from Beijing Jiankai Technology Co., Ltd.) The ratio is 1:2. Weigh mPEG-MAL-20KD and add it to the Δ23hKGF solution, stir the reaction for 2hr at 25°C and 100r / min, and stop the reaction by lowering the pH with hydrochloric acid. The modified Δ23hKGF (PEG-20K-Δ23KGF) solution was dialyzed overnight (dialysis fluid: 20mmNaAc, pH5.0), and the dialyzed PEG-20K-Δ23KGF solution was applied to an SP-Sepharose Fast Flow column (equilibration solution: 20mmNaAc, pH5.0) ), re-equilibration, eluted with a linear gradient of 50-500mm Nacl, collected the elution peak, and was detected by SDS-PAGE and HPLC to obtain PEG-20K-Δ23KGF ( figure 2 ).